Repligen Corporation's SEC filings document financial reporting, governance and public-company capital structure for a Nasdaq-listed life sciences company in bioprocessing technology. Recent Form 8-K reports attach earnings releases for quarterly and annual results, financial guidance and non-GAAP measures such as organic revenue, adjusted operating income, adjusted EPS and adjusted EBITDA.
The filing record also includes definitive proxy materials covering board matters, executive compensation and equity awards, along with Form 8-K disclosures on officer appointments, principal accounting officer responsibilities, financial reporting oversight and Sarbanes-Oxley-related infrastructure. Securities registration disclosures identify RGEN common stock, par value $0.01 per share, on the Nasdaq Global Select Market.
Repligen Corp. (RGEN) Chief Product Officer Brian Robb Douglass was awarded 700 restricted stock units and options to buy 675 common shares on October 6, 2026. The RSUs vest in equal annual installments over three years beginning on the first anniversary of the grant. The options have a $174.86 per-share exercise price; 225 shares vest on October 6, 2027, October 6, 2028, and October 6, 2029, and the options expire October 6, 2036. His directly held common stock following the RSU award was 8,685 shares.
As of September 30, 2026, FMR LLC and Abigail P. Johnson each reported beneficial ownership of 7,361,317.84 shares of Repligen Corp. (RGEN) common stock, or 13.0% of the class. FMR reported sole voting power over 7,345,276.55 shares, while Abigail P. Johnson reported 0.00 sole voting power. Each reported sole dispositive power over 7,361,317.84 shares. No other person’s interest in the common stock was more than 5% of total outstanding common stock.
Repligen Corporation’s Chief Executive Officer, Olivier Loeillot, exercised options for 4,202 common shares at $154.96 per share on October 5, 2026. He sold 4,202 shares at $190.00 per share and another 1,333 shares at $178.75 per share; both sales were made under a Rule 10b5-1 trading plan adopted on August 19, 2025. After the exercise, the reported option position was 8,405 options.
On October 6, 2026, Repligen Corporation (RGEN) completed its acquisition of BioLife Solutions. Each BioLife common share outstanding immediately before closing, other than treasury shares, shares owned by Repligen or either merger subsidiary, and shares for which appraisal rights were properly exercised and perfected and not withdrawn, converted automatically into a right to receive $11.25 in cash, without interest, and 0.1442 Repligen common shares; cash was paid in lieu of fractional shares. BioLife merged into Bravo Merger Sub II, LLC, which survived as Repligen's direct, wholly owned subsidiary.
BioLife ceased to exist as a separate legal entity, and its common stock will no longer be listed on Nasdaq. BioLife's CryoStor-led biopreservation media portfolio supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. Repligen intends to provide additional detail on the transaction's expected impact on its 2026 financial outlook during its upcoming third-quarter 2026 earnings call.
Repligen Corp (RGEN) is identified as the issuer in a Form 144 notice for Olivier Loeillot’s proposed sale of 4,202 common shares, with an aggregate market value of $798,380.00, through Fidelity Brokerage Services LLC. The notice lists October 5, 2026 as the approximate sale date and records four sales by Loeillot during the prior three months, dated August 20, September 4, September 21 and September 24, 2026.
Repligen Corp. Chief Executive Officer Olivier Loeillot had 1,248 shares withheld by the issuer on October 2, 2026, at a reported price of $181.70 per share, to satisfy tax withholding obligations arising upon release of restricted stock units. He directly held 47,121 shares after the transaction.
Olivier Loeillot reported a proposed sale of 1,333 Repligen Corp. (RGEN) common shares, with an aggregate market value of $238,273.75. Fidelity Brokerage Services LLC is listed as the broker, NASDAQ as the exchange, and October 5, 2026, as the approximate sale date. The notice lists the shares as acquired from the issuer through restricted stock vesting on October 2, 2026, with compensation as the payment nature.
Repligen (RGEN) CFO Jason K. Garland reported that 421 shares were withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations arising upon the release of restricted stock units. He directly held 18,408 shares after the transaction.
REPLIGEN CORP (RGEN) Chief Executive Officer Olivier Loeillot exercised options for 8,404 shares at an exercise price of $154.96 per share and 4,542 shares at $155.38 on September 24, 2026, then sold matching amounts at $190 per share. The sales were made under a Rule 10b5-1 trading plan adopted August 19, 2025.
Repligen Corp. is the issuer named in a notice listing 12,946 common shares for sale for officer and director Olivier Loeillot's account, with an aggregate market value of $2,459,740.00. The proposed sale is dated September 24, 2026, through Fidelity Brokerage Services LLC on NASDAQ. The notice also lists 12,946 shares acquired from the issuer through a stock option exercise for cash on September 24, 2026, and three prior sales: 5,426 shares on August 20, 3,035 on September 4, and 5,426 on September 21, 2026.